Transfusion medicine
-
Cryoprecipitate is an allogeneic blood product prepared from human plasma. It contains factors VIII, von Willebrand factor (vWF), fibrinogen, fibronectin and factor XIII. Its use was first described in the 1960s for treatment of patients with factor VIII deficiency. ⋯ Now, the most common use of cryoprecipitate is fibrinogen replacement in patients with acquired hypofibrinogenaemia and bleeding. Despite almost 50 years of use, evidence of efficacy is limited. This review provides an overview of the history of cryoprecipitate use, the current debates on the use of this product and future developments.
-
Transfusion medicine · Oct 2012
Multicenter StudyCryoprecipitate for transfusion: which patients receive it and why? A study of patterns of use across three regions in England.
Despite increasing interest in the use of fibrinogen concentrates, cryoprecipitate remains the major source of fibrinogen in England. ⋯ Wide variation in practice and dose suggests inconsistent practice and uncertainty in the evidence informing optimal use of cryoprecipitate.
-
Transfusion medicine · Oct 2012
Comparative StudyThe efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study.
Fibrinogen replacement is critical in major obstetric haemorrhage (MOH). Purified, pasteurised fibrinogen concentrate appears to have benefit over cryoprecipitate in ease of administration and safety but is unlicensed in pregnancy. In July 2009, the Irish Blood Transfusion Service replaced cryoprecipitate with fibrinogen. ⋯ Purified virally inactivated fibrinogen concentrate is as efficacious as cryoprecipitate in correcting hypofibrinogenaemia in MOH.
-
Transfusion medicine · Oct 2012
Multicenter Study Clinical TrialNational audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia.
Massive haemorrhage occurs in a variety of clinical settings resulting in consumptive and dilutional coagulopathies leading to hypofibrinogenaemia. ⋯ Fibrinogen concentrate can be used to correct hypofibrinogenaemia and may reduce blood product usage.